查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1678787

全球临床实验室仪器市场 - 2025 至 2033 年

Global Clinical Laboratory Instruments Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球临床实验室仪器市场规模达到 485.5 亿美元，预计到 2033 年将达到 916.1 亿美元，2025-2033 年预测期内的复合年增长率为 7.4%。

临床实验室仪器是医学实验室用来进行各种测试以有助于诊断、监测和治疗各种疾病的重要工具。这些仪器涵盖范围广泛，包括血液学分析仪、临床化学分析仪、免疫分析仪、显微镜和分子诊断设备。它们执行血液检测、组织分析以及病原体或特定生物标记的检测等关键功能。

市场动态：

驱动因素与约束因素

不断进步的技术

预计在预测期内，不断进步的技术将透过提高诊断测试的效率、准确性和速度，大大推动临床实验室仪器市场的发展。自动化、人工智慧 (AI) 整合、次世代定序 (NGS) 和即时诊断 (POC) 设备等创新正在彻底改变实验室运作。

此外，分子诊断和基因检测的进步使得各种疾病能够更早发现和个人化治疗，从而推动了对专用仪器的需求。随着技术的不断进步，临床实验室的效率越来越高，从而增加了先进仪器的采用，从而推动了临床实验室仪器市场的成长。

例如，2024 年 6 月，HORIBA 扩大了其屡获殊荣的紧凑型血液学仪器系列，推出了搭载红血球沉降率 (ESR) 的新型号。新型 Yumizen H550E（自动装填器）、H500E CT（闭管）和 Yumizen H500E OT（开管）可在 60 秒内提供全血 CBC/DIFF 与 ESR 结果的综合检测，为这些仪器原本就很广泛的功能添加了全面的炎症疾病评估功能。

先进临床实验室仪器价格昂贵

先进临床实验室仪器的高成本可能会限制资源匮乏地区的医疗机构使用，从而阻碍市场发展，因为这些地区的医疗机构可能没有财力投资昂贵的设备。这导致预算受限的地区采用尖端技术的速度较慢，尤其是公立医院或较小的私人诊所。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动态

  • 影响因素
    • 驱动程式
      • 技术进步
      • 增加医疗基础建设投资
    • 限制
      • 先进设备成本高昂
      • 维护和校准的复杂性
    • 机会
      • 对即时诊断（POC）的需求不断增长
    • 影响分析

第五章：产业分析

  • 市场领导者和先驱者
  • 新兴先锋和杰出参与者
  • 拥有最大销售品牌的成熟领导者
  • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 6 章：按类型

  • 自动化
  • 半自动化
  • 手动的

第 7 章：按产品类型

  • 临床化学仪器
  • 血液学分析仪
  • 免疫分析仪器
  • 微生物学仪器
  • 分子诊断仪器
  • 血气及电解质分析仪
  • 护理点 (POC) 设备
  • 其他的

第 8 章：按最终用户

  • 医院
  • 诊断实验室
  • 学术及研究机构
  • 诊所及门诊手术中心

第九章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 併购分析

第 11 章：公司简介

  • Beckman Coulter, Inc.
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 主要进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT 分析
  • Thermo Fisher Scientific Inc.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens Healthineers AG
  • bioMerieux
  • Leica Microsystems
  • Abbott Laboratories
  • Roche Diagnostics
  • Transasia Bio-Medicals
  • Labtron Equipment Ltd.

第 12 章：附录

简介目录
Product Code: LE9280

The global clinical laboratory instruments market reached US$ 48.55 billion in 2024 and is expected to reach US$ 91.61 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033.

Clinical laboratory instruments are essential tools used in medical laboratories to conduct a wide range of tests that help in diagnosing, monitoring, and treating various diseases. These instruments encompass a broad spectrum of devices, including hematology analyzers, clinical chemistry analyzers, immunoassay analyzers, microscopes, and molecular diagnostic equipment. They perform critical functions such as blood testing, tissue analysis, and the detection of pathogens or specific biomarkers.

Market Dynamics: Drivers & Restraints

Rising Technological Advancements

Rising technological advancements are expected to significantly drive the clinical laboratory instruments market over the forecast period by improving the efficiency, accuracy and speed of diagnostic testing. Innovations such as automation, artificial intelligence (AI) integration, next-generation sequencing (NGS) and point-of-care (POC) devices are revolutionizing laboratory operations.

Additionally, advancements in molecular diagnostics and genetic testing are enabling earlier detection and personalized treatment for various diseases, driving demand for specialized instruments. With continuous improvements in technology, clinical laboratories are becoming more efficient, which in turn increases the adoption of advanced instruments, thereby fueling the growth of the clinical laboratory instruments market.

For instance, in June 2024, HORIBA expanded its award-winning compact hematology instrument range with the launch of new models with the Erythrocyte Sedimentation Rate (ESR) on board. The new Yumizen H550E (autoloader), H500E CT (closed tube), and Yumizen H500E OT (open tube) offer combined testing for CBC/DIFF with ESR results from whole blood in 60 seconds, adding a comprehensive profile for inflammatory disease assessment to the instruments' already extensive functionality.

High Costs of Advanced Clinical Laboratory Instruments

The high costs of advanced clinical laboratory instruments can hinder the market by limiting access in low-resource regions, where healthcare facilities may not have the financial capacity to invest in expensive equipment. This leads to slower adoption of cutting-edge technologies in areas with budget constraints, particularly in public hospitals or smaller private clinics.

Segment Analysis

The global clinical laboratory instruments market is segmented based on the type, product type, end-user and region.

Clinical chemistry instruments in the product type segment are expected to dominate the clinical laboratory instruments market with the highest market share.

The clinical chemistry instruments segment is expected to dominate the clinical laboratory instruments market due to their broad application in routine diagnostics and the growing prevalence of chronic diseases like diabetes, cardiovascular conditions, and kidney disorders. These instruments are essential for testing a wide range of substances such as glucose, cholesterol, proteins, and electrolytes, making them indispensable in diagnosing and monitoring various health conditions.

Additionally, technological advancements in automation have significantly improved the speed, accuracy, and efficiency of clinical chemistry analyzers, enabling high-throughput testing, reducing human error, and lowering operational costs.

For instance, Beckman Coulter Diagnostics will unveil its new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer. The DxC 500 AU Chemistry Analyzer is one of several recent Beckman Coulter solutions designed to address the complete needs of healthcare systems that are looking to complement central hub laboratories by advancing the technology and capabilities of satellite and independent hospital laboratories. This makes clinical chemistry instruments vital in both high-volume hospital settings and smaller laboratories, ensuring their dominance in the market.

Geographical Analysis

North America is expected to dominate the clinical laboratory instruments market with highest market share

North America is expected to dominate the clinical laboratory instruments market due to its advanced healthcare infrastructure, strong presence of leading manufacturers, and substantial investments in healthcare. The region benefits from a high demand for diagnostic testing driven by the aging population, rising incidence of chronic diseases, and a focus on personalized medicine.

Technological advancements, including the adoption of molecular diagnostics, automated systems, and point-of-care devices, further bolster market growth. The robust regulatory framework, including FDA approvals, ensures high-quality standards for clinical laboratory instruments, while the region's strong research ecosystem, including top academic and clinical research institutions, drives continuous innovation.

For instance, in March 2023, PerkinElmer's Oxford Immunotec received the U.S. FDA approval for two additional cell isolation instruments, the Auto-Pure 24 and Auto-Pure 20B, for use with its T-Cell Select reagent kit in the T-SPOT.TB test workflow. All these factors combined ensure North America's continued dominance in the clinical laboratory instruments market.

Competitive Landscape

The global market players in the clinical laboratory instruments market are Beckman Coulter, Inc., Thermo Fisher Scientific Inc., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, bioMerieux, Leica Microsystems, Abbott Laboratories, Roche Diagnostics, Transasia Bio-Medicals and Labtron Equipment Ltd., among others.

Key Developments

  • In April 2023, Waters Corporation unveiled its next-generation Xevo TQ Absolute IVD mass spectrometer, expanding its family of MassTrak IVD LC-MS/MS Systems for clinical diagnostic applications.
  • In June 2024, Thermo Fisher Scientific introduced a new mass spectrometry platform, in addition to several updates to existing products at the American Society for Mass Spectrometry (ASMS) conference in Anaheim.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
  • Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global clinical laboratory instruments market report delivers a detailed analysis with 45 key tables, more than 46 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Product Type
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological Advancements
      • 4.1.1.2. Increased Investment in Healthcare Infrastructure
    • 4.1.2. Restraints
      • 4.1.2.1. High Costs of Advanced Equipment
      • 4.1.2.2. Complexity of Maintenance and Calibration
    • 4.1.3. Opportunities
      • 4.1.3.1. Increasing Demand for Point-of-Care (POC) Diagnostics
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Market Leaders and Pioneers
  • 5.2. Emerging Pioneers and Prominent Players
  • 5.3. Established leaders with largest selling Brand
  • 5.4. Market leaders with established Product
  • 5.5. CXO Perspectives
  • 5.6. Latest Developments and Breakthroughs
  • 5.7. Case Studies/Ongoing Research
  • 5.8. Regulatory and Reimbursement Landscape
  • 5.9. North America
  • 5.10. Europe
  • 5.11. Asia Pacific
  • 5.12. Latin America
  • 5.13. Middle East & Africa
  • 5.14. Porter's Five Force Analysis
  • 5.15. Supply Chain Analysis
  • 5.16. Patent Analysis
  • 5.17. SWOT Analysis
  • 5.18. Unmet Needs and Gaps
  • 5.19. Recommended Strategies for Market Entry and Expansion
  • 5.20. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.21. Pricing Analysis and Price Dynamics
  • 5.22. Key Opinion Leaders

6. By Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Automated*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Semi-automated
  • 6.4. Manual

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Clinical Chemistry Instruments*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Hematology Analyzers
  • 7.4. Immunoassay Instruments
  • 7.5. Microbiology Instruments
  • 7.6. Molecular Diagnostics Instruments
  • 7.7. Blood Gas & Electrolyte Analyzers
  • 7.8. Point-of-Care (POC) Devices
  • 7.9. Others

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Diagnostic Laboratories
  • 8.4. Academic & Research Institutes
  • 8.5. Clinics & Ambulatory Surgical Centers

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Beckman Coulter, Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio
      • 11.1.2.1. Product Description
      • 11.1.2.2. Product Key Performance Indicators (KPIs)
      • 11.1.2.3. Historic and Forecasted Product Sales
      • 11.1.2.4. Product Sales Volume
    • 11.1.3. Financial Overview
      • 11.1.3.1. Company Revenue's
      • 11.1.3.2. Geographical Revenue Shares
      • 11.1.3.3. Revenue Forecasts
    • 11.1.4. Key Developments
      • 11.1.4.1. Mergers & Acquisitions
      • 11.1.4.2. Key Product Development Activities
      • 11.1.4.3. Regulatory Approvals etc.
    • 11.1.5. SWOT Analysis
  • 11.2. Thermo Fisher Scientific Inc.
  • 11.3. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 11.4. Siemens Healthineers AG
  • 11.5. bioMerieux
  • 11.6. Leica Microsystems
  • 11.7. Abbott Laboratories
  • 11.8. Roche Diagnostics
  • 11.9. Transasia Bio-Medicals
  • 11.10. Labtron Equipment Ltd.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us